Related Experiment Video

Updated: Jul 20, 2026

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

RIZ1 repression is associated with insulin-like growth factor-1 signaling activation in chronic myeloid leukemia cell

E Pastural1, N Takahashi, W-F Dong

  • 1Genomic Medicine and Pathobiology Group and Department of Pathology, University of Saskatchewan, Saskatoon, SK, Canada.

Oncogene
|September 6, 2006
PubMed

Insights

RIZ1, a tumor suppressor, inhibits chronic myelogenous leukemia (CML) progression by reducing insulin-like growth factor-1 (IGF-1) signaling. Restoring RIZ1 may offer a new therapeutic strategy for CML.

Area of Science:

  • Oncology
  • Molecular Biology
  • Epigenetics

Background:

  • RIZ1 (pr domain-containing protein 14) is a histone methyltransferase with reduced expression in various cancers.
  • Blastic transformation in chronic myelogenous leukemia (CML) correlates with RIZ1 loss and decreased activity.
  • RIZ1 exhibits tumor suppressor properties, inhibiting proliferation and promoting apoptosis and differentiation in CML models.

Purpose of the Study:

  • To elucidate the molecular mechanisms underlying RIZ1's tumor suppressor functions in CML.
  • To investigate the relationship between RIZ1 and insulin-like growth factor-1 (IGF-1) signaling in CML.

Main Methods:

  • cDNA microarrays to identify RIZ1-regulated genes.
  • Chromatin immunoprecipitation (ChIP) assays to assess RIZ1 binding and histone methylation.
  • Use of IGF-1 blocking antibodies and analysis of downstream signaling pathways (ERK1/2, AKT).

Main Results:

  • RIZ1 expression negatively impacts IGF-1 signaling pathway components.
  • RIZ1 associates with IGF-1 promoter regions and increases histone H3 lysine 9 methylation.
  • RIZ1 overexpression reduces IGF-1 receptor activation and downstream signaling, impacting CML cell viability.

Conclusions:

  • RIZ1 acts as a tumor suppressor in CML by downregulating IGF-1 signaling.
  • Targeting the IGF-1 pathway presents a potential therapeutic strategy for acute-phase CML.

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Co-activators and Co-repressors02:04

Co-activators and Co-repressors

Gene transcription is regulated by the synergistic action of several proteins that form a complex at a gene regulatory site. This is observed in eukaryotes, where the regulation of gene expression is a complex process. Regulatory proteins in eukaryotes can broadly be classified into two types – regulators that bind directly to specific DNA sequences and co-regulators that associate with regulatory proteins but cannot directly bind to the DNA. These co-regulators are further divided into...